

05 Jul 2021 |

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: vaccine efficacy and the Delta and Delta Plus variants; breakthroughs in CRISPR gene editing and microbiome therapies; and the pandemic's possible effect on regulatory pathways.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 2 July 2021, including: vaccine efficacy and the Delta and Delta Plus variants; breakthroughs in CRISPR gene editing and microbiome therapies; and the pandemic's possible effect on regulatory pathways.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Vaccines Show Signs Of Efficacy Against Delta Variant, But Is It Enough?](#)" - Scrip, 29 Jun, 2021.)

(Also see "[Roche, Lilly Antibody Cocktails Threatened By Delta Plus Variant But More Evidence Needed](#)" - Scrip, 25 Jun, 2021.)

(Also see "[Intellia Achieves Gene-Editing Breakthrough With First In Vivo CRISPR Therapy](#)" - Scrip, 28 Jun, 2021.)

(Also see "[Amgen CEO Shines Light On Opportunities For Accelerated Drug Pathways](#)" - Scrip, 28

Jun, 2021.)

(Also see "[Ferring Chief Muses On Moment Of Truth For Microbiome Therapy](#)" - Scrip, 24 Jun, 2021.)

[Click here to explore this interactive content online](#) 